key: cord-0953942-rfi6q6vk
authors: To, Albert; Wong, Teri Ann S.; Lieberman, Michael M.; Thompson, Karen; Ball, Aquena H.; Pessaint, Laurent; Greenhouse, Jack; Daham, Nisrine; Cook, Anthony; Narvaez, Brandon; Flinchbaugh, Zack; Van Ry, Alex; Yalley-Ogunro, Jake; Andersen Elyard, Hanne; Lai, Chih-Yun; Donini, Oreola; Lehrer, Axel T.
title: A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant
date: 2022-03-09
journal: ACS Infect Dis
DOI: 10.1021/acsinfecdis.1c00600
sha: 4807798004fa46cf5dbcea9f4b412026e7707481
doc_id: 953942
cord_uid: rfi6q6vk

[Image: see text] FDA-approved and emergency use-authorized vaccines using new mRNA and viral-vector technology are highly effective in preventing moderate to severe disease; however, information on their long-term efficacy and protective breadth against severe acute respiratory syndrome coronavirus 2 variants of concern (VOCs) is currently scarce. Here, we describe the durability and broad-spectrum VOC immunity of a prefusion-stabilized spike (S) protein adjuvanted with liquid or lyophilized CoVaccine HT in cynomolgus macaques. This recombinant subunit vaccine is highly immunogenic and induces robust spike-specific and broadly neutralizing antibody responses effective against circulating VOCs (B.1.351 [Beta], P.1 [Gamma], and B.1.617 [Delta]) for at least three months after the final boost. Protective efficacy and postexposure immunity were evaluated using a heterologous P.1 challenge nearly three months after the last immunization. Our results indicate that while immunization with both high and low S doses shorten and reduce viral loads in the upper and lower respiratory tract, a higher antigen dose is required to provide durable protection against disease as vaccine immunity wanes. Histologically, P.1 infection causes similar COVID-19-like lung pathology as seen with early pandemic isolates. Postchallenge IgG concentrations were restored to peak immunity levels, and vaccine-matched and cross-variant neutralizing antibodies were significantly elevated in immunized macaques indicating an efficient anamnestic response. Only low levels of P.1-specific neutralizing antibodies with limited breadth were observed in control (nonvaccinated but challenged) macaques, suggesting that natural infection may not prevent reinfection by other VOCs. Overall, these results demonstrate that a properly dosed and adjuvanted recombinant subunit vaccine can provide protective immunity against circulating VOCs for at least three months.

that can result in hospitalization and/or death. 6−9 Transmission occurs through respiratory droplets during close contact with asymptomatic or presymptomatic infected individuals, as well as symptomatic patients. 10−12 The synergistic relationship between infectivity and high transmissibility with low virulence has contributed to the ongoing global public health crisis and the emergence of more transmissible and potentially more pathogenic variants of concern (VOCs). Longitudinal cross-sectional studies have indicated that only a fraction of asymptomatic to mild and moderate SARS-CoV-2 natural infections of humans results in detectable neutralizing antibodies months after recovery, 13−15 and current evidence suggests that convalescent immunity may only provide transient protection. 16−18 Furthermore, the degree of immune evasion witnessed in vitro by spike (S) protein variants and the increasing occurrence of reinfection 19−23 have raised the question whether previous infection or vaccine-derived immunity can provide heterologous protection against further transmission and limit additional mutation of circulating VOCs, even while protection against severe disease and mortality has been sustained to date.

Some VOCs show increased transmissibility, cause more severe disease than original strains, and demonstrate greater immune evasion to neutralizing antibodies as they harbor mutations at sites facilitating viral fusion and at critical epitopes in the N-terminal (NTD) and receptor-binding domains (RBD). 24, 25 The B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) variants contain the same set of mutations, K417T, E484K, and N501Y, while the B.1.617 (Delta) carries L452R and T478K mutations, all of which are associated with enhanced infectivity and reduced serum neutralization. 26−28 These antigenic changes have abolished potent neutralizing epitopes targeted by monoclonal antibody therapeutics 29 and antibodies elicited by mRNA vaccination. 30 Natural reinfection with the VOC strains after the original strain infection, and vice versa, has been documented. 20,31−34 Despite this, crossneutralization of convalescent sera from patients infected with nonvariants and mRNA-immunized individuals suggests that the parental spike (S) protein in current vaccines affords some degree of protection. 35−37 Phase 1−3 clinical trials of novel mRNA (Moderna mRNA-1273 and Pfizer-BioNTech BNT162b2) and viral-vector (Johnson & Johnson−Janssen Ad26.COV2.S) platforms, utilizing the original Wuhan-Hu-1 S protein, 38−40 have shown these vaccines to be highly protective with 94−95 and 67% efficacy against COVID-19 disease, respectively, 41−43 and they all elicit uniformly high protection against severe disease/death (i.e., >85%). Post hoc sequencing during clinical trials of these and other vaccine platforms in variant-dominant regions has revealed a slightly lower efficacy against B.1.1.7 and B.1.351 variants, albeit usually remaining above the 50% protection threshold. 44, 45 Attempts at predicting protection based on immune correlates, such as cross-neutralizing antibodies, have shown that vaccinated individuals have a 2to 8-fold reduction in titers against current VOCs as IgG levels wane, which are nonetheless believed to confer a degree of resistance against infection. 46−49 However, these samples were taken during the peak period of the humoral response and may not be accurate predictors of protection months onward when the likelihood of infection is greater. Thus, understanding the decay in antibody responses months after the final boost is an essential endpoint in vaccine development.

Evaluating a delayed vaccine response in nonhuman primate (NHP) models can provide valuable foresight into the relationship between waning immunity and protection, especially against VOCs. In this study, we describe the immunogenicity and protective efficacy of a recombinant prefusion spike subunit (based on the reference SARS-CoV-2 strain, Wuhan-Hu-1) adjuvanted with liquid or lyophilized (dry) CoVaccine HT, a squalane-in-water nanoemulsion adjuvant containing immunostimulatory sucrose fatty acid sulfate esters, 50 in cynomolgus macaques. Both the zeta potential and emulsion droplet size of CoVaccine HT are maintained when reconstituted with distilled water. 51 Other investigators have shown that infection with SARS-CoV-2 (prototype strain) produced COVID-19-like disease in this species and reflects similar viral shedding kinetics and lung pathology to human infections. 52, 53 We have previously demonstrated that our vaccine candidate elicits a broadspectrum IgG response including high neutralizing antibody (NtAb) titers against the prototypic SARS-CoV-2 and VOCs, specifically B.1.351 and P.1, and an in vitro antigen-specific IFN-γ secreting response from immune splenocytes taken from Swiss Webster mice. 54 To elaborate on our understanding of the elicited immunological response, we assessed the vaccine efficacy using a delayed challenge scheme with the P.1 VOC to delineate how the maturation or decay of the humoral response affects protection from a heterologous SARS-CoV-2 strain. Neutralizing antibody responses to the vaccine-matched WA1/2020 strain and VOCs B.1.351, P.1, and B.1.617 were also determined just prior to challenge and 14 days postchallenge (to assess anamnestic responses). Furthermore, we characterize the viral kinetics and histopathological changes postchallenge in the lower and upper respiratory tracts of control (nonvaccinated but challenged) and protected NHPs. To our knowledge, this is the first published account of P.1 VOC challenge in NHPs.

Spike Antigen with Either Liquid or Lyophilized CoVaccine HT Elicits a Durable Humoral Response. A stably transformed Drosophila S2 cell line, without subculturing, yielded approximately 30 mg/L of the prefusion spike protein. Purification using CR3022 mAb immunoaffinity chromatography did not negatively affect the structural integrity of the purified protein ( Figure S1A ), and sizeexclusion analysis revealed that the spike antigen is primarily homogeneous ( Figure S1B ).

To evaluate immunogenicity, 12 cynomolgus macaques were assigned into four groups (n = 3 per group) and received two immunizations with 5 (Group A) or 25 μg (Groups B and C) of the liquid prefusion spike trimer (S) antigen formulated with either the lyophilized (Groups A and C) or liquid (Group B) CoVaccine HT adjuvant or one dose of a colyophilized CoVaccine HT-adjuvanted control containing an unrelated viral glycoprotein antigen (Group D) ( Figure 1A ). The two doses were administered within a three-week interval, and all NHPs were challenged with the P.1 isolate 12 weeks postboost (∼3 months, study week 15). Wuhan-Hu-1 S-and RBDspecific IgG titers were measured by a multiplexed microsphere immunoassay (MIA) using insect cell-expressed antigens coupled onto spectrally distinct, magnetic beads as described previously. 54 Serum S-specific IgG concentrations were interpolated using a standard curve generated from S-specific human IgG purified from vaccinated individuals ( Figure 1B) .

pubs.acs.org/journal/aidcbc Article RBD-specific IgG titers were read out as median fluorescence intensity (MFI) ( Figure S2 ). All NHPs immunized with the adjuvanted S at both antigen doses seroconverted after the prime (week 3) with S-specific antibodies in the range of 20− 70 μg/mL, and peak serum IgG concentrations were detected two weeks after the boost (week 5) in the range of 70−753 μg/mL. Macaques given a 25 μg dose of S demonstrated a greater IgG response to the antigen compared to those receiving 5 μg. RBD-specific IgG titers followed a similar trend. As expected, animals in Group D receiving an unrelated antigen did not develop any detectable S-specific IgG during this phase of the study. S-specific IgG remained detectable 12 weeks after the boost (week 15) although IgG concentrations dropped by 3.0-to 9.9-fold relative to the prior peak titer. The titer of NtAb against the prototype WA1/2020 strain was determined using a standard PRNT with the wild-type (WT) virus ( Figure 1C ). NtAb from one animal in Group C was detectable after the prime (week 3). All S-immunized NHPs developed a potent neutralizing response, peaking two weeks after the boost (week 5) and generally remaining stable one week later (week 6). The group receiving 5 μg of the antigen showed the greatest variability. Nearly all immunized NHPs maintained neutralization capacity, with PRNT 50 greater than 1:150 dilution, 12 weeks after the final immunization (week 15). NtAbs from groups receiving 25 μg of S either remained stable or decreased up to 3.0-fold, while the group receiving 5 μg of S declined by ∼2.9−9.2-fold. A similar reduction in serum neutralization was also verified using a surrogate rVSV-SARS-CoV-2 S PRNT assay ( Figure S3) .

A Recombinant Subunit Vaccine Induces Stable Neutralizing Antibodies against VOCs. Circulating SARS-CoV-2 VOCs can evade vaccine-induced antibody responses and are associated with breakthrough infections in those fully immunized, especially as antibody titers wane. 55−61 To determine whether an adjuvanted, prototypic Wuhan-Hu-1 S subunit can generate durable cross-variant neutralizing antibodies, PRNTs using WT B.1.351, P.1, and B.1.617 isolates were determined with sera collected at the time of peak neutralization and 12 weeks after the final immunization, a time point at which antibody titers are expected to have waned. At week 6, potent neutralization of the B.1.351, P.1, and B.1.617 VOCs was detected, although 10.7-, 10.7-, and 5.7-fold lower, respectively, compared to WA1/2020 in all vaccine groups ( Figure 2A ). The decrease in neutralization against B.1.351 and B.1.617 is consistent with reports of titers in sera from NHPs and humans immunized with mRNA vaccines that show ∼8and ∼5-fold reduction, respectively. 62−67 As antibody titers waned 10 weeks later (study week 15), the gap between neutralization titers against the WA1/2020 strain to the VOC isolates narrowed to 4.5-, 5.3-, and 5.1-fold differences, respectively ( Figure 2B ), driven by a proportionally larger decline in WA1/2020-specific neutralizing activity. At this later time point, all S-immunized macaques, except for a single macaque in Group A, maintained a detectable PRNT 50 titer greater than 1:40. A few macaques in Groups B and C demonstrated greater VOC neutralization at week 15 compared to week 6, suggesting a refinement or "maturation" of the humoral response toward neutralizing epitopes during this interval. Overall, 25 μg of the S protein generated a more durable and greater variant-neutralizing response than the lower antigen dose.

Immunization with Recombinant Subunits Reduces Viral Burden from Delayed P.1 (Gamma) Challenge. The characterization of the prototype strain and B.1.351 variant infections in NHP models has been described previously. 52,53,68−70 Here, we characterize the clinical signs and histological events of a P.1 VOC infection in cynomolgus (A) Twelve cynomolgus macaques were separated into four groups and given either 5 or 25 μg of the S protein formulated with either the liquid or reconstituted, lyophilized CoVaccine HT adjuvant. Two doses were administered IM three weeks apart, and the serum was collected at indicated time points. Macaques were challenged IN and IT with a total of 1 × 10 6 TCID 50 of the SARS-CoV-2 P.1 strain. (B) Serum Wuhan-Hu-1 S-specific IgG kinetics measured using a MIA with purified, human S-specific IgG standards to estimate serum concentration. Each sample was diluted 1:5000 and plotted as the average of duplicate measurements. Duplicate values varied by <10% of each other. The dotted line indicates the limit of quantification (LOQ, ≤4 μg/mL). Individual values falling below the LOQ were set to 1/2 LOQ. Significance was calculated using one-way ANOVA followed by Dunnett's multiple comparison to Group D at each time point. (C) WA1/2020 neutralizing antibody kinetics measured using a WT SARS-CoV-2 PRNT assay. Curve-fitted PRNT 50 titers were calculated using a sigmoidal dose−response curve. The dotted line indicates the limit of detection (LOD, ≤1: 20) . Individual values falling below the LOD were set to 1/2 LOD. Significance was calculated using the Kruskal−Wallis test followed by Dunn's multiple comparison (*p ≤ 0.05, **p ≤ 0.01). macaques and determine whether a prefusion spike subunit formulated with CoVaccine HT is effective at reducing the viral load against a circulating VOC after a 12-week interval following the final immunization. All NHPs were challenged with a total of 1 × 10 6 TCID 50 of the P.1 isolate using simultaneous intranasal and intratracheal inoculation routes. None of the NHPs challenged developed visible clinical signs of respiratory disease throughout the study, consistent with WA1/2020 strain-infected cynomolgus macaques. 52 No changes in the responsiveness, respiratory rate, respiratory effort, nasal or ocular discharge, or cough were documented during the observation period. The core body temperature also did not change. A slight, and sometimes intermittent, decrease in weight was observed in some macaques across all experimental groups; however, most returned to near the initial weight by day 14 ( Figure S4A ,B). A single control macaque in Group D had sustained weight loss throughout and at the end of the observation period. The weight change did not correlate with a higher viral load nor the degree of lung histopathology.

Bronchioalveolar lavages (BAL) from the lower respiratory tract and nasal and oral swabs (NS and OS, respectively) from the upper respiratory tract were collected at days 2, 4, 7, 10, and 14 after challenge to detect infectious virus, genomic RNA, or signs of viral replication. High levels of infectious virus, 5.8 and 5.0 log 10 TCID 50 titers, were recovered two days postchallenge from the NS and BAL, respectively, from Group D control macaques ( Figure 3A ,D and Figure S5A ,B).

Infectious virus continued to be detectable in both anatomic sites until at least day 7 postchallenge before becoming undetectable on day 10. All S-immunized NHPs presented TCID 50 titers at least 1−2 log 10 lower than those of control macaques in both locations at all time points throughout the study, indicating a degree of protection conferred by both 5 and 25 μg S formulations of the subunit vaccine. Low levels of infectious virus in the BAL were recovered on day 2 in two out of the three macaques from both Groups A and B, while no culturable virus was recovered from all Group C macaques at any time point throughout the study. Except for a single macaque in Group B on day 4 only, no virus could be cultured from the BAL of any S-immunized macaques from this time point onward. Infectious virus from the NS was recoverable from immunized macaques throughout the study period and was variable between groups; however, these macaques on average had TCID 50 at least 1−2 log 10 below those of control macaques. Only low levels of virus could be recovered on day 7 from two macaques from Group C before dropping to undetectable levels at day 10. No virus could be seen in Groups A and B from day 7 onward.

Quantitative RT-PCR was used as an additional measurement for the viral load. We detected the presence of viral RNA and viral replication throughout the 14-day study period in both the lower ( Figure Quantification of viral RNA showed that both 5 and 25 μg immunization had reduced the viral load by approximately 1−2 log 10 RNA copies/mL (or swab) over Group D control macaques, corroborating the TCID 50 results. Viral replication in most of the immunized macaques was low or undetectable by days 7 and 10 in the BAL and NS, respectively, which is 3−4 days earlier than in control macaques. Similarly, replication in the oral cavity was undetectable at least 3 days earlier in most of the S-immunized macaques than in the control group, suggesting a reduced potential for transmission. By contrast, high levels of viral RNA and replication, between 5 and 6 log 10 RNA copies/mL, were observed in these control macaques before gradually resolving at day 10. Altogether, reduced viral loads and earlier clearance at all tested anatomic locations in Group A, B, and C macaques indicate a degree of durable protection from P.1 VOC infection provided by an adjuvanted protein subunit vaccine.

High-Dose Spike Antigen Reduces Lung Histopathology Caused by P.1 (Gamma) Challenge. To evaluate vaccine efficacy against COVID-19-like pathology, a section slide from each lung lobe and the bronchi was prepared from each macaque and stained with hematoxylin and eosin to survey for histopathological changes indicative of acute lung injury. The histopathological scoring system based on the presence/severity of edema, intra-alveolar and interstitial inflammation, perivascular lymphocytic cuffing, and an increased bronchiolar-associated lymphoid tissue (BALT) is outlined in Table S1 . A cumulative average score was determined for each macaque based on the evaluation of these five characteristics per section for a total of 30 scores ( Figure 4A ). Significant differences in the cumulative average scores for each vaccine formulation vs controls were determined using one-way ANOVA followed by the Dunnett's multiple comparison test. Macaques in the control Group D appeared to have developed mild to moderate respiratory disease. The lower cumulative GMT scores of Groups B and C, . Individual values falling below the LOD were set to 1/2 LOD. Significance was calculated using the Kruskal− Wallis test followed by Dunn's multiple comparison to Group D at each time point. Horizontal bars within the symbols mark the GMT of each group. Horizontal bars above the groups of symbols indicate the group comparisons, which showed statistically significant differences (*p ≤ 0.05).

immunized with 25 μg of S, suggest that these animals, except for a single macaque, were protected from lung pathology, while all Group A (immunized with 5 μg of S) macaques appeared to have developed mild disease despite exhibiting lower viral loads. Week 15 WA1/2020 NtAb levels were determined to be inversely correlated, although weakly, with histopathology scores using the Spearman's correlation test (r = −0.682, p = 0.0178) ( Figure 4B ). Week 15 prechallenge neutralizing antibody levels were lower in animals with higher histopathology scores, a trend seen with breakthrough infections in fully immunized individuals. 56 The moderate disease seen in the control animals is demonstrated in Figure   5A , where a representative low-power magnification shows a distribution of lymphocytic perivascular cuffing and clusters of intra-alveolar macrophages. In contrast, immunized animals (especially those receiving the higher antigen dose) appeared to have milder disease without these pathological changes ( Figure 5B ). For reference, a lung section from an uninfected macaque is shown in Figure S8 . Macaques developing mild to moderate disease exhibited absent to moderate, focal and multifocal edema and perivascular cuffing with marked lymphocytic infiltration ( Figure 6A−D) . Syncytia of intraalveolar multinucleated giant cells surrounded by acute and eosinophilic inflammatory infiltrates ( Figure 6A ) or increased The cumulative average histopathology score was determined by averaging the scores of six sections cut from each lobe and the bronchi. The presence and severity of edema, intra-alveolar inflammation, perivascular cuffing, increased BALT, and interstitial inflammation were determined and assigned scores ranging from 0 to 3. Significant differences in lung histopathology were calculated using one-way ANOVA followed by Dunnett's multiple comparison to Group D with the scores from each section (30 scores per macaque) as replicates. Horizontal bars mark the GMT of each group (**p ≤ 0.01, ****p ≤ 0.0001). (B) Correlation between histopathology scores and WA1/2020-specific PRNT 50 titers were determined using the Spearman's correlation test.

ACS Infectious Diseases pubs.acs.org/journal/aidcbc Article intra-alveolar macrophages with interstitial lymphocytic inflammation, in addition to alveolar septal thickening and complete perivascular cuffing, can be seen in a moderately diseased control macaque ( Figure 6B ,C). A proteinaceous edema fluid filling alveolar spaces was also observed in unprotected macaques ( Figure 6D ). While these histopathological changes were also noticed in protected macaques, the findings appeared less severe ( Figure 6E ,F). A section from a protected macaque revealed a few intra-alveolar multinucleated giant cells without an increase in intra-alveolar macrophages, lymphocytic vascular cuffing, or interstitial inflammation ( Figure 6E ). Similarly, only partial lymphocytic perivascular cuffing with adjacent alveolar epithelial hyperplasia was noticed without an increased intraepithelial macrophage infiltrate and normal alveolar septal thickness in immunized macaques receiving 25 μg of S ( Figure 6F ). P.1 Challenge Recalls a Broadly Neutralizing Anamnestic Response in Immunized Macaques and a Variant-Specific Primary Neutralizing Response in Naïve Macaques. To better understand the immunological basis of events happening after late challenge (12 weeks postbooster immunization) and to determine if P.1 challenge triggered an anamnestic response in immunized NHPs, postchallenge S-specific IgG concentrations and PRNT 50 titers were measured from sera collected upon necropsy at day 14 after challenge. Late P.1 challenge significantly boosted serum IgG concentrations to levels attained at the postimmunization peak at week 6, with less variance between animals, suggesting that a recall response was triggered by the heterologous infection ( Figure 7A ). Vaccine-matched (WA1/2020) and VOC-neutralizing (i.e., B.1.351, P.1, and B.1.617) antibody levels were also all significantly boosted to levels attaining or surpassing the peak levels generated through the initial immunization by 5-fold and higher than 20-fold, respectively ( Figure 7B and Figure S3 ). Unsurprisingly, the greatest increase from prechallenge neutralization was against the P.1 challenge isolate. Group A showed slightly higher P.1 NtAbs than Group B and C macaques and was the only group to have significantly higher titers across different variants. The lower degree of histopathology seen in Groups B and C may indicate that 25 μg of S with either form of CoVaccine HT provides greater long-term protection. In Group D control macaques, P.1 challenge generated low levels of NtAbs compared to immunization alone, and it was only cross-reactive with the B.1.351 isolate and not to WA1/2020 nor B.1.617 isolates. This suggests that primary infection with one isolate of SARS-CoV-2 does not generate broad immunity against other variants in contrast to vaccine-derived immunity, which is more broadly cross-reactive with VOCs, even months after peak immunity is observed.

Understanding the durability and breadth of vaccine-generated immunity is critical for predicting long-term protection during the COVID-19 pandemic and for informing policy on strategic resource deployment to facilitate equitable vaccine access. Diversifying the types of vaccines currently used beyond mRNA and viral vectors to include other vaccine platforms, such as thermostable protein subunit vaccines, 71−73 can bolster global availability by mobilizing more vaccines to resourcepoor areas, or overcoming antivector immunity and adverse effects, by using this platform as a booster to restore preexisting natural or vaccine-induced immunity. 74−76 We have demonstrated that two doses of a subunit vaccine consisting of a prefusion S trimer (Wuhan-Hu-1) formulated with liquid or lyophilized CoVaccine HT reduce the viral load and provide sufficient, durable, and cross-variant protection from mild to moderate disease lasting for at least three months after the final boost. This supports previous findings in rhesus macaques that S trimer-based subunit protein vaccines are highly immunogenic and generate long-lasting, robust antibody responses. 77 Furthermore, using a two-step purification method of immunoaffinity chromatography followed by a size-exclusion polishing step results in a homogeneous antigen composition and reduces host−cell carry-over plaguing conventional purification strategies for protein subunits. 78 Also promising is the prospect that the adjuvant, CoVaccine HT, can be lyophilized and reconstituted simply with water for injection and still retain its functionality. This technology has been previously used to develop mono-and multivalent filovirus vaccine formulations. Those studies demonstrated that single-vial, lyophilized formulations preserved the higher-order antigen structure and the biophysical properties of the were detected throughout the extended study period and inversely correlated with the viral load and lung damage. Neutralization against the B.1.351 and P.1 VOCs was equivalently reduced compared to the WA/2020 isolate immediately following the booster and suggested that E484K and N501Y may play a critical role in antibody evasion early on; however, this reduction equilibrated at the three-month time point across all VOCs tested while still affording sufficient protection. This report supports growing evidence that the Wuhan-Hu-1 S peptide sequence encoded by highly effective mRNA, viral-vectored, and subunit protein vaccines generates immunity that affords protection against circulating VOCs, 45,46,51,79,80 even months after the final vaccine dose when antibody titers are waning. Furthermore, we noticed that a few macaques receiving the higher antigen dose had developed increasingly potent cross-variant neutralizing titers immediately prior to viral challenge, which were greater than the titers observed during the peak humoral response. This suggests that a potentially remaining antigen depot or persistence of APCs may foster continued accumulation of somatic mutations and affinity maturation in memory B cells 81, 82 beyond the initial vaccination phase. This study is also the first to describe the course of infection and histopathology of a SARS-CoV-2 P.1 infection in an NHP model. Consistent with what was described in WA1/2020infected cynomolgus macaques, 52,53 macaques challenged with the P.1 isolate did not develop an elevated temperature, nor did they show observable signs of respiratory disease. The viral load in the upper and lower respiratory tract peaked early during infection two days after challenge and gradually decreased to undetectable sgRNA levels by day 14 in unprotected animals, similar to viral kinetics described in another study using the same inoculating dose (1 × 10 6 TCID 50 ) but with an early pandemic isolate. 53 Although P.1 is estimated to be upwards of 2.4-fold more transmissible, 26 it is unclear whether the higher viral load observed during peak P.1 replication in this study compared to time-matched reports for a nonvariant isolate is a characteristic of P.1 replication or a discrepancy between readouts from different RT-PCR procedures. However, we show that immunization with both 5 and 25 μg doses of S effectively reduces the viral load in both upper and lower respiratory tracts, implying a lower likelihood of viral transmission even in mildly symptomatic macaques. Histopathological examination of lung and bronchial sections in unprotected macaques confirmed mild to moderate disease, which was abrogated in immunized macaques. COVID-19-like disease observed in this model consisted of increased intraalveolar and interstitial infiltration, as well as giant syncytial cells, similar to previous observations. 52,64,83 While both high and low doses of the S antigen generate statistically negligible differences in humoral responses during peak immunity, it is clear from our findings that higher antigen doses, at least with CoVaccine HT, produce a more durable and protective response at later time points. Late P.1 challenge induced an anamnestic response in all immunized macaques that restored S-specific antibody titers to peak serum concentrations seen shortly after the booster immunization and significantly enhanced vaccine-matched and VOC-neutralizing antibody titers. In most of the macaques receiving 25 μg of S, the immune recall occurred with little to no disease. The durability and cross-variant neutralizing nature of immune responses generated by mRNA and viral vectors have been documented up to six months or later. 63,84−86 However, breakthrough infections, particularly with variant strains, have been reported even in the presence of detectable and high-level NtAbs. 55, 57, 60, 63, 87 Anamnestic responses in fully immunized NHPs have been characterized previously with homologous and B.1.351 variant challenge and agree with our observations that viral challenge boosts functional antibody levels. Our analysis shows that viral challenge with a heterologous strain rapidly boosts not only homologous and challenge strain-specific NtAbs but also NtAbs against the unencountered variants, B.1.351 and B.1.617, underpinning the broad-spectrum potential of subunit protein vaccines. In contrast, control macaques, receiving no S antigen but infected with the P.1 variant, developed moderate levels of P.1 NtAbs that are only cross-neutralizing with B.1.351 and barely neutralize WA1/2020 and B.1.617, suggesting that natural infection with one variant of SARS-CoV-2 may confer only limited protection against other VOCs. Of course, further affinity maturation could not be observed here as the study ended 14 days after challenge.

The small size of our treatment groups (n = 3) is a limitation of our study and may therefore not provide enough statistical power to strongly correlate antibody concentrations to the viral load or the histopathology score. Furthermore, we cannot directly compare the outcome of our study to other studies that evaluate vaccine efficacy soon after the final immunization when immunity is greatest, as vaccine efficacy is known to decline over time. Likewise, we could not benchmark the efficacy of our vaccine formulation when the immunity is greatest at week 5; however, our late challenge scheme accurately reflects the current urgent need for decisions about timing and candidates for possible booster vaccinations during the pandemic situation as it provides useful information regarding the real-life durability and breadth of vaccine protection. Finally, while our results and evidence from other COVID-19 vaccine serological studies demonstrate that the prototypic spike sequence confers sufficient protection against B. 1.351, P.1, and B.1.617 VOCs, 30,46,47,65,67,79 protection against highly divergent variants such as the BA.1 (Omicron) variant may require a second booster for greater coverage. 88−92 Further investigation is required to determine the full utility of protein vaccines to serve as a prime or boost in combination with other vaccines for this purpose.

In conclusion, we show that a two-dose regimen of a prefusion-stabilized trimeric S subunit protein vaccine formulated with the lyophilizable CoVaccine HT adjuvant reduces viral burden and high antigen doses can confer durable cross-variant immunity. Future efforts will therefore focus on developing a thermostabilized vaccine formulation in a singlevial format, potentially enabling facile worldwide distribution. Kingdom) was lyophilized as previously described 51 and reconstituted with sterile water before mixing with the antigen. Each group consisted of both male and female cynomolgus macaques (n = 3 for each formulation) weighing between 2.8 and 8.2 kg. Cynomolgus macaques of Groups A−C were immunized intramuscularly (IM) in both deltoids (split dose) at weeks 0 and 3, and control animals were immunized only once at week 0. Prechallenge sera were collected at weeks 0, 3, 5, 6, and 15. Challenge at week 15 with the SARS-CoV-2 P.1 variant, hCoV-19/Japan/TY7-501/2021, and TY7-501 (BI-OQUAL-generated stock [lot no. 031921-1215] in Calu-3 cells from seed stock no. TY7-501) was performed with an inoculum dose of 5 × 10 5 TCID 50 /mL administered to each animal in volumes of 1 mL by intratracheal and intranasal injection at each site. Nasal and oral swabs (NS and OS, respectively) were collected on days 2, 4, 7, 10, and 14 after challenge. Bronchoalveolar lavage (BAL) samples were collected on days 2, 4, 7, and 10 after challenge. Necropsies and lung tissue collection were performed at the endpoint of the study at day 14 postchallenge. Samples were immediately processed and subsequently stored at −80°C prior to analysis. S-specific serum IgG concentrations were determined using a microsphere immunoassay (MIA; see below). NtAbs were measured using wild-type and rVSV-SARS-CoV-2 S PRNTs (see below). The viral load in the NS, OS, and BAL was measured using plaque assays and quantification of genomic and subgenomic N transcript RNA (see below). Lung and bronchial tissues were processed and H&E-stained to delineate histopathological signs of disease in each animal.

The plasmid was generated to express the prefusion, proteaseresistant, and trimeric transmembrane (TM)-deleted spike (S) glycoprotein from SARS-CoV-2 as described previously. 54 Modifications to the gene include the removal of the furin and S2′ cleavage site, the addition of two prolines between the heptad repeat 1 and the central helix region, and a foldon trimerization domain. Briefly, Drosophila S2 cells were transfected with the S gene using Lipofectamine LTX with a PLUS reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions using ExCell420 media (Sigma-Aldrich, St. Louis, MO). Serial passage of the cell culture into fresh media spiked with 300 μg/mL hygromycin B generated a stably transformed cell line. To verify S protein expression, transformants were induced at a density of 1 × 10 6 cells/mL with culture medium containing 200 μM CuSO 4 , and the supernatant was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting one week later. To scale up protein expression, the cell culture was expanded to 1 L in a 2 L Cellbag bioreactor on a WAVE bioreactor system (Cytiva, Marlborough, MA) and induced with 200 μM CuSO 4 the following day. The culture supernatant was harvested one week later, and sodium azide (Sigma-Aldrich, St. Louis, MO) was added up to 0.01% (w/v) before cold storage or purification.

The recombinant S protein was purified from clarified cell culture supernatants by immunoaffinity chromatography (IAC) using the SARS-CoV-2 cross-reactive mAb CR3022 (provided by Mapp Biopharmaceutical, RRID: AB_2848080) coupled to NHS-activated Sepharose at a concentration of 10 mg/mL. The antigen was eluted with a glycine buffer (pH 2) in tandem into a HiPrep 26/10 desalting column (Cytiva, Marlborough, MA) equilibrated with PBS. The oligomeric content was evaluated by size-exclusion chromatography using a HiLoad 16/600 column (GE Healthcare, Piscataway, NJ) equilibrated with PBS. The S protein was eluted as a single peak, and the final product migrated as two bands, corresponding to the monomer and the trimer on SDS-PAGE, under denaturing conditions, and was reactive to CR3022 mAb on a Western blot. Antigens were filter-sterilized with a 0.22 μm syringe filter (Cytiva, Marlborough, MA) and stored at −80°C until use.

Analysis of Antibodies by Multiplex Microsphere Immunoassay. The IgG antibody titers in sera were measured using a multiplex microsphere-based immunoassay as described previously. 54,93−95 Spectrally distinct, magnetic MagPlex microspheres (Luminex Corporation, Austin, TX) were coupled to purified S, RBD, or bovine serum albumin (BSA). A mixture of the antigen-coupled beads was incubated with sera diluted with PBS + 1% BSA and 0.02% Tween 20 (PBS-BT) at 1:5,000 or 1:10,000 in black-sided 96-well plates for 3 h at 37°C with agitation. Bound IgG was detected using 1 μg/mL red phycoerythrin (R-PE)-conjugated goat antihuman IgG antibodies (Jackson ImmunoResearch, Inc., West Grove, PA) and resuspended in a MAGPIX drive fluid before being analyzed on a MAGPIX Instrument (Luminex Corporation, Austin, TX).

To determine S-specific IgG concentrations in the sera, the median fluorescence intensity (MFI) readouts of each sample were interpolated against a standard curve generated using purified human IgG at concentrations in the range of 7.44− 1000 ng/mL. To produce the antibody standard, IgG was purified from pooled sera of COVID-19-vaccinated human volunteers using protein A affinity chromatography followed by immunoaffinity chromatography (IAC) using NHS-Sepharose (Cytiva, Marlborough, MA) coupled with recombinant S to select for S-specific IgG. The purity was assessed using SDS-PAGE, and the antibody concentration was quantified using UV 280 absorbance. The resulting MFI values were plotted against the log 10 -transformed concentrations and fitted using a sigmoidal dose−response, variable-slope model (GraphPad Prism, San Diego, CA). The resulting curves yielded r 2 values of >0.99 with a well-defined top and bottom and the linear range of the curve. The experimental S-specific IgG concentrations in experimental samples were determined by interpolation on the standard curves, multiplied by the dilution factor, and plotted as antibody concentrations (ng/mL).

Recombinant Vesicular Stomatitis Virus (rVSV) Neutralization Assay. Replication-competent rVSV expressing the SARS-CoV-2 S protein (Wuhan-Hu-1) was generated as described previously, 96 and the virus stocks were amplified in Vero E6 cells. For the plaque reduction neutralization test (PRNT), individual NHP serum samples were heat-inactivated at 56°C for 30 min. Six 3-fold serial dilutions of serum samples, starting at 1:40 dilution, were prepared and incubated with 100 plaque-forming units (PFU) of rVSV-SARS-CoV-2 S at 37°C for 1 h. Antibody−virus complexes were added to Vero cell monolayers in six-well plates and incubated at 37°C for another hour followed by the addition of overlay media mixed with 1% agarose. Seventy-two hours later, cells were fixed and stained with a solution containing 1% formaldehyde, 1% methanol, and 0.05% crystal violet overnight for plaque enumeration. Neutralization titers (PRNT 50 ) were generated using a variable-slope, nonlinear regression, with upper and lower constraints (100 and 0% neutralization, respectively), using Prism 9 (GraphPad Software, San Diego, CA).

TCID 50 and Wild-Type SARS-CoV-2 Virus PRNT 50 Assay. TCID 50 and PRNT 50 assays were performed in a biosafety level 3 facility at BIOQUAL, Inc. (Rockville, MD). The TCID 50 assay was conducted by the addition of 10-fold graded dilutions of samples to Vero TMPRSS2 cell monolayers. Serial dilutions were performed in the cell culture wells in quadruplicates. Positive (virus stock of known infectious titer in the assay) and negative (medium only) control wells were included in each assay setup. The plates were incubated at 37°C and 5.0% CO 2 for 4 days. The cell monolayers were visually inspected for CPE, i.e., complete destruction of the monolayer with cellular agglutination. The TCID 50 value was calculated using the Reed−Muench formula. 97 For samples that had less than three CPE positive wells on the first dilution, the TCID 50 could not be calculated using the Reed−Muench formula, and these samples were assigned a titer of below the limit of detection (i.e., <2.7 log 10 TCID 50 /mL). The TCID 50 value of the positive control should be within 2-fold of the expected value.

To measure neutralization, sera from each NHP were diluted to 1:10 followed by a 3-fold serial dilution. Diluted samples were then incubated with 30 plaque-forming units of wild-type SARS-CoV-2 USA-WA1/2020 (BEINR-52281), B.1.351 (BEI NR-55282), or P.1. (BEI NR-54982) variants, in an equal volume of culture medium for 1 h at 37°C. The serum−virus mixtures were added to a monolayer of confluent Vero E6 cells and incubated for 1 h at 37°C in 5% CO 2 . Each well was then overlaid with culture medium containing 0.5% methylcellulose and incubated for three days at 37°C in 5% CO 2 . The plates were then fixed with methanol at −20°C for ACS Infectious Diseases pubs.acs.org/journal/aidcbc Article 30 min and stained with 0.2% crystal violet for 30 min at room temperature. PRNT 50 titers were calculated using a variableslope, nonlinear regression, with upper and lower constraints (100 and 0% neutralization, respectively), on Prism 9 (GraphPad Software, San Diego, CA). Histopathology. NHP lung tissue specimens from each lung lobe and bronchi were harvested at the time of necropsy and preserved in 10% formalin before processing and parafilmembedded, fixed, and stained with hematoxylin and eosin. For each NHP, one section from the bronchi and one section from each lobe on the right and left lung were selected for scoring, for a total of six sections. Pathologic findings on each slide were scored on a scale of 0−2 for intra-alveolar edema, the amount of the BALT (bronchiolar-associated lymphoid tissue), and the presence of interstitial inflammation and 0−3 for perivascular inflammatory infiltrates (cuffing) and intraalveolar inflammation (see Table S1 .) Scores for the six slides from each macaque were tabulated, and a cumulative average score was calculated for each NHP using a total of 30 scores as replicates.

SARS-CoV-2 Viral Genomic and Subgenomic RNA Quantitative RT-PCR. The presence of viral RNA and viral replication in the BAL, NS, and OS after SARS-CoV-2 P.1 strain challenge was determined by quantitative RT-PCR. RNA was isolated from 200 μL of sample using a QIAamp MinElute Virus spin kit (Qiagen, Frederick, MD). To generate a control for the amplification reaction, RNA was isolated from the applicable virus stock using the same procedure. The number of copies for the control was calculated using known RNA weights per mol. A master mix was prepared containing Taqpolymerase, obtained from a TaqMan RT-PCR kit (Bioline catalog no. BIO-78005), RT, an RNAse inhibitor, a primer pair at a 2 μM concentration (2019-nCoV_N1-F: 5′-GAC CCC AAA ATC AGC GAA AT-3′ and 2019-nCoV_N1-R: 5′-TCT GGT TAC TGC CAG TTG AAT CTG-3′), and a probe (2019-nCoV_N1-P: 5′-FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ1-3′) at a concentration of 2 μM. For the reactions, 45 μL of the master mix and 5 μL of the sample RNA were added to the wells of a 96-well plate. All samples were tested in triplicate. Control RNA was prepared to contain 10 6 −10 7 copies per 3 μL. Eight 10-fold serial dilutions of control RNA were prepared and produced a standard curve with a range of 1−10 7 copies per reaction. For amplification, the plate was placed in an Applied Biosystems 7500 sequence detector and amplified using the following program: 48°C for 30 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 s, and 1 min at 55°C. Duplicate samples of each dilution were prepared as described above. If the copy number exceeded the upper detection limit, then the sample was diluted as needed. The number of copies of RNA per mL was calculated by interpolation from the standard curve and multiplying by the reciprocal of the 0.2 mL extraction volume. This gave a practical range of 50 to 5 × 10 8 RNA copies per mL for BAL samples, and for nasal and oral swabs, the viral loads were given per swab.

The RT-PCR assay for the sgRNA utilized primers and a probe specifically designed to amplify and bind to a region of the N gene mRNA from the coronavirus, which was not packaged into the virion. The signal was compared to a known standard curve of the plasmid containing the sequence of part of the messenger RNA and calculated to give copies per mL. The control RNA was prepared to contain 10 7 copies. Seven 10-fold serial dilutions of control RNA were prepared using Buffer AVE and generated a standard curve with a range of 1− 10 6 copies/reaction. Duplicate samples of each dilution were prepared as described above with the primer pair (SG-N-F: CGATCTCTTGTAGATCTGTTCTC and SG-N-R: GGTGAACCAAGACG CAGTAT) and the probe (FAM-TAACCAGAATGGAGAACGCAGTGGG-BHQ). If the copy number exceeded the upper detection limit, then the sample was diluted as needed. For amplification, the plate was placed in an Applied Biosystems 7500 sequence detector and amplified using the following program: 48°C for 30 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 s, and 1 min at 55°C. The number of copies of RNA per mL was calculated by interpolation from the standard curve and multiplying by the reciprocal of the 0.2 mL extraction volume. This gave a practical range of 50 to 5 × 10 7 RNA copies per mL for harvested samples.

Statistical Analysis. Statistically significant differences between the geometric mean of IgG concentrations or MFI in groups given different vaccine formulations at each time point were determined using two-way ANOVA followed by Dunnett's multiple comparison. Comparisons of PRNT 50 values between vaccine formulations were done using the Kruskal−Wallis test followed by the Dunn's multiple comparison test. Correlations between IgG or PRNT titers to the viral load in the BAL and NS were examined using the nonparametric Spearman's correlation test. Differences between histopathological scores in different treatment groups were calculated using one-way ANOVA followed by the Dunnett's multiple comparison test with the cumulative scores of all slides per macaque as replicates. All statistical analyses were completed using GraphPad Prism 9 software (San Diego, CA). 

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Neurologic Features in Severe SARS-CoV-2 Infection

Coagulation abnormalities and thrombosis in patients with COVID-19

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

Northwell COVID-19 Research Consortium. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Presumed Asymptomatic Carrier Transmission of COVID-19

Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data

Temporal dynamics in viral shedding and transmissibility of COVID-19

Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan

Antibodies in Persons with Mild Covid-19

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2

Confirmed Reinfection with SARS-CoV-2 Variant VOC-202012/01

Symptomatic SARS-CoV-2 Reinfection in a Healthy Healthcare Worker in Italy Confirmed by Whole-Genome Sequencing

A case of SARS-CoV-2 reinfection in Ecuador

Genomic evidence for reinfection with SARS-CoV-2: a case study

Spike mutation D614G alters SARS-CoV-2 fitness

The Indian SARS-CoV-2 Genomics Consortium; The Genotype to Phenotype Japan (G2P-Japan) Consortium; The

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

(29) FDA. Fact Sheet for Health Care Providers Emergency Use Authorization (EDA) of Bamlanivimab and Etesevimab

Early detection of SARS-CoV-2 P.1 variant in Southern Brazil and reinfection of the same patient by P.2

Severe reinfection with South African SARS-CoV-2 variant 501Y.V2

7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France

Characterization of a new SARS-CoV-2 variant that emerged in Brazil

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Issues Emergency Use Authorization for Third COVID-19 Vaccine. Food and Drug Administration

ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Efficacy of the

Covid-19 Vaccine against the B.1.351 Variant

Julkunen, I. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Sucrose fatty acid sulphate esters as novel vaccine adjuvant

Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvant

Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice

Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant

Regev-Yochay, G. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Vaccine breakthrough infection and onward transmission of SARS-CoV-2 Beta (B.1.351) variant

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners

Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings

Durability of mRNA-1273 vaccine

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Impact of circulating SARS-CoV-2 variants on mRNA vaccineinduced immunity

Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Establishment of an African green monkey model for COVID-19 and protection against re-infection

Immunogenicity and Protective Efficacy of a Highly Thermotolerant

Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design

Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses

Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein

Recombinant protein vaccines against SARS-CoV-2

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised

SARS-CoV-2 vaccines: anamnestic response in previously infected recipients

Optimizing immunization protocols to elicit broadly neutralizing antibodies

Epidemiology of SARS-CoV-2

mRNA-1273 Study Group. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Durable Humoral and Cellular Immune Responses 8 Months after Ad26. COV2.S Vaccination

The Upenn Covid Processing Unit

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

Effect of serum heat-inactivation and dilution on detection of anti-WNV antibodies in mice by West Nile virus E-protein microsphere immunoassay

Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization

Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine

A simple method of estimating fifty percent end points